AI assistant
Sending…
Lexaria Bioscience Corp. — Director's Dealing 2022
May 19, 2022
34983_dirs_2022-05-19_ef64d1ff-9c6d-40b5-b235-7bf3f78143b4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Lexaria Bioscience Corp. (LEXX)
CIK: 0001348362
Period of Report: 2022-05-18
Reporting Person: REESE ALBERT L JR (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-05-18 | common shares | A | 1700 | $2.008 | Acquired | 2617 | Direct |
| 2022-05-19 | common shares | A | 1501 | $2.01 | Acquired | 4118 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| common shares | 917 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Options | $4.8 | 2026-02-01 | Common Shares (3400) | 3400 | Direct |
| Stock Options | $3.39 | 2027-03-08 | Common Shares (3400) | 6800 | Direct |
More from Lexaria Bioscience Corp.
Interim / Quarterly Report
2026
Apr 13
Director's Dealing
2026
Mar 18
Delisting Announcement
2026
Feb 6
Regulatory Filings
2026
Jan 28
Declaration of Voting Results & Voting Rights Announcements
2026
Jan 28
Capital/Financing Update
2026
Jan 14
Delisting Announcement
2026
Jan 14
Interim / Quarterly Report
2026
Jan 13
Capital/Financing Update
2025
Dec 29
Regulatory Filings
2025
Dec 19